FHTX
Foghorn Therapeutics Inc.
FHTX's fundamentals are strong: revenue more than tripled and its operating margin went from −353% to 2.1%, though free cash flow was negative. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
FHTX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Weak | |
| Strong |
FHTX's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
FHTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 34x | $2.05 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
FHTX's PE is 34x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
FHTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect FHTX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
FHTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.06 | +$1.12 |
| Q2 2026 | -$0.99 | +$0.13 |
| Q1 2026 | -$1.17 | +$0.12 |
| Q4 2025 | -$1.18 | +$0.40 |
| Q3 2025 | -$1.06 | +$0.86 |
| Q2 2025 | -$1.12 | +$0.83 |
| Q1 2025 | -$1.29 | +$0.91 |
| Q4 2024 | -$1.58 | +$0.76 |
FHTX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
FHTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.5M | +925% |
| Q2 2026 | $16.1M | +113% |
| Q1 2026 | $3.3M | -45% |
| Q4 2025 | $9.2M | +224% |
| Q3 2025 | $8.2M | +4.4% |
| Q2 2025 | $7.6M | +9.7% |
| Q1 2025 | $6M | +18% |
| Q4 2024 | $2.9M | -50% |
FHTX's revenue is growing: $84M last quarter, up 925% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 68% | +295 points |
| Q2 2026 | -55% | +224 points |
| Q1 2026 | -660% | -275 points |
| Q4 2025 | -258% | +582 points |
| Q3 2025 | -227% | +79 points |
| Q2 2025 | -279% | +108 points |
| Q1 2025 | -385% | +173 points |
| Q4 2024 | -841% | -399 points |
FHTX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over FHTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
FHTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$18.3M | +$610K |
| Q2 2026 | -$17.9M | +$3.1M |
| Q1 2026 | -$25.3M | -$1.3M |
| Q4 2025 | -$22.3M | +$2.7M |
| Q3 2025 | -$18.9M | +$2.5M |
| Q2 2025 | -$21M | +$4.5M |
| Q1 2025 | -$24M | +$5.5M |
| Q4 2024 | -$25M | +$2.6M |
FHTX has burned cash in almost every quarter: −$84M over the past year, against −$89M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over FHTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
FHTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +2M shares |
| 1 year | +15% | +9.6M shares |
| 3 years | +73% | +30.6M shares |
| 5 years | +96% | +35.6M shares |
| Available history | +228% | +50.5M shares |
FHTX has 73M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over FHTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
FHTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -21.0x | Net Cash |
FHTX has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
FHTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 3.6 | Oversold |
FHTX's weekly RSI is 35 (neutral) and its Stochastic is 4 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
FHTX PE vs Healthcare Sector
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
FHTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.17 | 5.5% below |
| 20 week MA | $4.10 | 50% below |
| 50 week MA | $4.60 | 55% below |
| 100 week MA | $4.62 | 56% below |
| 200 week MA | $5.55 | 63% below |
FHTX is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
FHTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.1 | $24.6 | +36% |
| 2021 | $24.6 | $21.2 | -14% |
| 2022 | $21.2 | $5.70 | -73% |
| 2023 | $5.70 | $6.45 | +13% |
| 2024 | $6.45 | $4.82 | -25% |
| 2025 | $4.82 | $5.40 | +12% |
| 2026 YTD | $5.40 | $2.05 | -62% |
FHTX has finished lower in three of the last six years. It's down 62% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over FHTX on returns for 2026, with the stronger performance.